← 返回

嵌合抗原受体治疗在肿瘤学之外的应用:文献计量学与可视化分析

英文原题:Application of chimeric antigen receptor therapy beyond oncology: A bibliometric and visualized analysis.

查看英文原题

Application of chimeric antigen receptor therapy beyond oncology: A bibliometric and visualized analysis.

PubMed 2024/02/06(内容时间) Curr Res Transl Med Q3 · IF 3(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

研究概要

近年来,嵌合抗原受体疗法在肿瘤学以外的领域取得了快速进展。我们探索了该领域的热点与研究方向。希望本研究能为未来的临床研究提供参考和方向。

研究思路结论见上方概要

嵌合抗原受体疗法在肿瘤学之外的领域受到越来越多关注。尽管近年来涌现了大量出版物,但已开展的文献计量学研究却很少。我们的目标是系统总结并可视化分析嵌合抗原受体疗法在肿瘤学之外领域的文献,并探索该领域的热点。

选择Web of Science核心合集作为数据源,根据检索策略于2022年12月23日进行数据检索。使用CiteSpace 6.1.R6和Vosviewer 1.6.18对出版物进行分析,并探索研究热点和方向。

共纳入来自42个国家/地区的516个机构的1832位作者撰写的338篇文献进行分析。文献数量逐年稳步增长。美国是主要贡献者,宾夕法尼亚大学是领先机构。Frontiers in Immunology发表的论文数量最多。Kitchen SG、Riley JL和Scott DW是该领域最高产的研究者。关键词聚类分析确定HIV、自身免疫性疾病、移植相关疾病和COVID-19为嵌合抗原受体治疗在肿瘤学之外领域的主要焦点领域。

展开英文摘要原文

Chimeric antigen receptor therapy beyond oncology has gained increasing attention. While a substantial number of publications have emerged in recent years, there has been a paucity of conducted bibliometric studies. Our objective is to systematically summarize and visually analyze the literature in the field of chimeric antigen receptors therapy beyond oncology and explore hotspots in this field.

Web of Science Core Collection was selected as the data source, and the data was retrieved on December 23, 2022, according to the search strategy. CiteSpace 6.1.R6 and Vosviewer 1.6.18 were used to analyze publications and explore research hotspots and directions.

A total of 338 publications written by 1832 authors from 516 institutions in 42 countries/regions were selected for the analysis. The number of publications is steadily increasing annually. The United States emerged as the primary contributor, and University of Pennsylvania was the leading institution. Frontiers in Immunology boasted the highest number of published papers. Kitchen SG, Riley JL, and Scott DW were the most productive researchers in this field. The keyword cluster analysis identified HIV, autoimmune diseases, transplant related diseases and COVID-19 as the primary focus areas within the realm of chimeric antigen receptor therapy beyond oncology.

The advancement of chimeric antigen receptor therapy beyond oncology has witnessed rapid progress in recent years. We have explored the hotspots and research directions in this field. It is hoped that this study could provide references and directions for future clinical researches.

论文信息

作者
Yang L、He J、Liu J、Xie T、Tang Q
第一作者单位
Department of Rheumatology and Immunology, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China; Clinical Medical Research Center for Systemic Autoimmune Diseases in Hunan Province, Changsha, Hunan, China.China
通讯作者单位
Department of Rheumatology and Immunology, the Second Xiangya Hospital, Central South University, Changsha, Hunan, China; Clinical Medical Research Center for Systemic Autoimmune Diseases in Hunan Province, Changsha, Hunan, China. Electronic address: tangqi8824@csu.edu.cn.China
期刊
Current research in translational medicine2024 Sep
原文标识
PubMed 38452444 · DOI 10.1016/j.retram.2024.103442